WEBULL
WebtradeDownload

Natera (NTRA) Posted Strong Q2 Results, Is The Stock Fully Priced?

Simply Wall St · 2d ago

Natera (NTRA) is back in focus after reporting Q2 2026 earnings on August 6, with revenue of US$752.75 million and a narrower net loss, alongside fresh regulatory progress for Signatera in Japan.

See our latest analysis for Natera.

Natera’s share price has eased in the short term, with a 1-month share price return of down 5.65% and a 7-day share price return of down 1.59%. Momentum over longer periods remains strong, reflected in a 90-day share price return of 36.62% and a 1-year total shareholder return of 88.11% as investors weigh improving earnings trends and fresh regulatory milestones for Signatera.

If the latest Natera news has you thinking about other healthcare opportunities, it may be worth reviewing a curated list of 42 healthcare AI stocks.

Natera now has a larger revenue base, narrower losses and fresh regulatory momentum in Japan. The question is whether a stock that is up 88.11% over 1 year still lines up sensibly with that progress.

Most Popular Narrative: 5.9% Undervalued

The most followed Natera narrative points to a fair value of $282.14 compared with the last close at $265.38, which frames the current discount in valuation terms.

Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera); this will likely boost top-line revenue.

Read the complete narrative.

Curious what kind of revenue path, margin profile, and earnings power would need to line up to support that fair value and the implied future multiple? The full narrative spells out the growth rates, profitability shift, and valuation bridge that connect today’s $265.38 share price to that $282.14 target.

Result: Fair Value of $282.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Natera narrative can be knocked off course if key clinical trials disappoint, or if reimbursement and pricing terms end up tighter than analysts expect.

Find out about the key risks to this Natera narrative.

Another Angle On Natera’s Valuation

The first narrative points to a modest 5.9% discount to a fair value of $282.14 using analyst assumptions. Our DCF model tells a very different story. It points to a fair value of $538.52, which is far above the current $265.38 share price and suggests a very large modeled gap. The question is whether you think Natera’s future cash flows can really live up to that.

Look into how the SWS DCF model arrives at its fair value.

NTRA Discounted Cash Flow as at Aug 2026
NTRA Discounted Cash Flow as at Aug 2026

Next Steps

With sentiment looking mixed after such a strong 1-year run for Natera, it makes sense to move quickly, test the numbers, and form your own view with the help of 2 key rewards and 1 important warning sign.

Looking for more Natera investment ideas?

If Natera has sharpened your focus, do not stop here. Fresh opportunities are emerging across the market and you will miss them if you stay on just one stock.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.